nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification paper paperNew
2025, 17, v.66 1759-1763
从“浊害清和”论肿瘤微环境与恶性演进的关系及微观辨治
基金项目(Foundation): 国家自然科学基金(81904101); 中华中医药学会雏鹰计划中医临床青年人才研修项目(SCAN0004)
邮箱(Email): cihuichen@126.com;
DOI: 10.13288/j.11-2166/r.2025.17.005
摘要:

认为“浊害清和”理论契合现代医学中肿瘤微环境失稳的病机特征,形成浊邪化膏、结瘀、热变、郁闭(即富脂微环境、高凝、炎性微环境及缺氧微环境)的核心病机演变过程。“黜浊”之法成为截断肿瘤转向恶性预后的核心要义,提出中气失序、浊邪化膏始酿痰浊,多以运中健脾之法利痰浊,改善肿瘤治疗耐药;血脉凝滞、浊邪结瘀促生瘀浊,故以活血调营之法散瘀浊,抑制新生血管生成和血行转移;虚火上浮、热燔浊邪终致毒浊,治以养阴解毒之法清毒浊,降低炎症反应并增强机体免疫功能;木失条达、浊邪滞缓化为郁浊,应以舒达肝木之法泄郁浊,抑制肿瘤生长发展。结合不同病势进行加减配伍,旨在靶向调控肿瘤微环境,延缓肿瘤恶性演进,冀以为肿瘤病证的精准辨治提供指导。

Abstract:

The theory of "turbidity impairing clarity and harmony" aligns with the pathological features of tumor microenvironment destabilization in modern medicine. It describes a core pathogenic evolution in which turbid pathogens transform into phlegm-turbidity, blood stasis, heat toxicity, and stagnation, which correspond to lipid-rich microenvironment, hypercoagulable and inflammatory microenvironment, and hypoxic microenvironment. The principle of "eliminating turbidity" becomes central to intercepting malignant prognosis of tumors. It is proposed that when center qi loses regulation, turbid pathogens transform into phlegm-turbidity, which should be treated by strengthening the spleen and regulating the middle to resolve phlegm-turbidity, thereby improving resistance to tumor therapies. When blood circulation is obstructed and turbid pathogens form stasis, promoting blood circulation and regulating the nutrient qi can disperse stasis-turbidity, inhibit angiogenesis, and prevent hematogenous metastasis. When deficient fire flares upward and heat scorches turbid pathogens into toxic turbidity, nourishing yin and detoxifying can clear toxic turbidity, reduce inflammatory responses, and enhance immune function. When the liver loses its coursing function and turbid pathogens stagnate into depressive turbidity, soothing the liver and relieving constraint can eliminate depressive turbidity, thereby suppressing tumor growth. Modifications are applied according to different stages of disease, aiming to target the regulation of the tumor microenvironment, slow malignant progression, and provide guidance for precise syndrome differentiation and treatment of tumor-related conditions.

参考文献

[1]MARX V. Tracking metastasis and tricking cancer[J].Nature, 2013,494(7435):133-136.

[2]KUNDU M, BUTTI R, PANDA VK, et al. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer[J]. Mol Cancer, 2024,23(1):92.

[3]陈志南,边惠洁,杨向民.肿瘤微环境稳态重塑可阻抑肿瘤进展[J].空军军医大学学报,2024,45(7):723-731.

[4]何伟,胡勇,佟雅婧.肿瘤免疫抑制及炎性微环境的中医病机[J].现代中医药,2022, 42(6):1-5.

[5]程海波,周仲瑛.癌毒病机科学内涵的现代诠释[J].南京中医药大学学报,2021,37(5):637-641.

[6]韩欣璞,许博文,李杰.基于“寒气生浊”探讨胃癌微环境的微观辨治[J].中医杂志,2022,63(12):1135-1138.

[7]郭栴子,朱中博,杨硕,等.从浊毒理论辨治乳腺癌肿瘤相关脂肪微环境[J].中医药导报,2020,26(16):112-115.

[8]马倩,常蕊,庞龙.基于“浊害清和”理论探讨糖尿病视网膜病变的病机与辨治[J].中华中医药杂志,2024,39(5):2623-2626.

[9]GERBER SA, RYBALKO VY, BIGELOW CE,et al.Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth[J]. American J Pathology, 2006, 169(5):1739-1752.

[10]CHOI HJ, ARMAIZ PENA GN, PRADEEP S, et al. Antivascular therapies in ovarian cancer:moving beyond antiVEGF approaches[J]. Cancer Metastasis Rev,2015,34(1):19-40.

[11]NIEMAN KM, KENNY HA, PENICKA CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth[J]. Nat Med, 2011,17(11):1498-1503.

[12]LI Y, YU C, DENG W. Roles and mechanisms of adipokines in drug resistance of tumor cells[J]. Eur J Pharmacol,2021,899:174019. doi:10. 1016/j. ejphar. 2021. 174019.

[13]刘俊汝,郁春艳,郑小燕,等.富脂微环境通过PPARγ/ABCG2途径促进三阴性乳腺癌细胞的多药耐药[J].天津医科大学学报,2023,29(3):280-287,294.

[14]何伟,张亚密,胡勇,等.肿瘤微环境新生血管的病络机制[J].天津中医药,2021, 38(12):1553-1556.

[15]陶倩倩,张雷,杜晓鹂,等.血小板介导的肿瘤微环境调控:活血化瘀中药的新靶点[J].中南药学,2021,19(6):1212-1218.

[16]SARTORICINTRA AR, MARA CS, ARGOLO DL,et al.Regulation of hypoxia-inducible factor-1α(HIF-1α)expression by interleukin-1β(IL-1β), insulin-like growth factorsⅠ(IGF-Ⅰ) andⅡ(IGF-Ⅱ) in human osteoarthritic chondrocytes[J]. Clinics, 2012, 67(1):35-40.

[17]BAMBACE NM, HOLMES CE. The platelet contribution to cancer progression[J]. J Thromb Haemost,2011,9(2):237-249.

[18]WALSH TG, METHAROM P, BERNDL MC. The functional role of platelets in the regulation of angiogenesis[J]. Platelets, 2014, 26(3):1-13.

[19]张恩欣,侯超.周岱翰解毒治癌十法[N].中国中医药报,2016-05-20(04).

[20]刘丽荣,刘译鸿,张海波.肿瘤炎性微环境及其对肿瘤相关巨噬细胞抑制的研究进展[J].疑难病杂志,2020, 19(2):193-197.

[21]葛焰森,肖冲,夏孟蛟,等.论“解表法”干预肿瘤缺氧微环境[J].湖北中医杂志,2019,41(2):50-53.

[22]刘俊汝,郁春艳,郑小燕,等.富脂微环境通过PPARγ/ABCG2途径促进三阴性乳腺癌细胞的多药耐药[J].天津医科大学学报,2023, 29(3):280-287.

[23]王晓开,周琳,刘春英.补中益气汤联合分子靶向药物治疗肺腺癌的临床研究[J].辽宁中医杂志,2017, 44(6):1256-1258.

[24]张潇潇,朱广辉,刘浩,等.以脂质代谢重编程为核心探讨康莱特注射液抗肿瘤多靶点效应机制[J].辽宁中医杂志,2021,48(12):49-52.

[25]可燕,蒋嘉烨,王现珍,等.三七根及花总皂苷抗肿瘤细胞诱导的血小板聚集研究[J].中药材,2010,33(1):96-99.

[26]叶欢,阮君山,王少明.隐丹参酮抗肿瘤转移的研究进展[J].中国药理学通报,2014,30(7):893-896.

[27]王生,赵杨,陶丽,等.川芎嗪对肿瘤介导的血液高凝的影响[J].中国药理学通报,2012,28(5):709-715.

[28]白涛.益气养阴汤联合贝伐珠单抗注射液治疗卵巢癌的效果[J].医学信息,2021,34(6):172-174.

[29]谢敏,胥冰,潘艳芳,等.山仙颗粒对H22肝癌移植瘤微环境中淋巴细胞活性的调控作用[J].现代中西医结合杂志,2022,31(3):299-302.

[30]吴静远,许博文,李杰,等.基于网络药理学探讨疏肝健脾方治疗抑郁相关乳腺癌的分子生物学机制[J].海南医学院学报,2022, 28(10):766-773.

[31]WANG XZ, XIA L, ZHANG XY, et al. The multifaceted mechanisms of Paeoniflorin in the treatment of tumors:state-of-the-art[J]. Biomed Pharmacother,2022,149:112800. doi:10. 1016/j. biopha. 2022. 112800.

基本信息:

DOI:10.13288/j.11-2166/r.2025.17.005

中图分类号:R273

引用信息:

[1]孙千惠,程孟祺,段桦,等.从“浊害清和”论肿瘤微环境与恶性演进的关系及微观辨治[J].中医杂志,2025,66(17):1759-1763.DOI:10.13288/j.11-2166/r.2025.17.005.

基金信息:

国家自然科学基金(81904101); 中华中医药学会雏鹰计划中医临床青年人才研修项目(SCAN0004)

发布时间:

2025-08-29

出版时间:

2025-08-29

检 索 高级检索

引用

GB/T 7714-2015 格式引文
MLA格式引文
APA格式引文